Global Meningococcal Disease Vaccine Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Meningococcal Disease Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Meningococcal Disease Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Meningococcal Disease Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Meningococcal Disease Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Meningococcal Disease Vaccine players cover AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi and Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
LPI (LP Information)' newest research report, the “Meningococcal Disease Vaccine Industry Forecast” looks at past sales and reviews total world Meningococcal Disease Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Meningococcal Disease Vaccine sales for 2023 through 2029. With Meningococcal Disease Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Meningococcal Disease Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Meningococcal Disease Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Disease Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Meningococcal Disease Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Disease Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Disease Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Disease Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Meningococcal Disease Vaccine market?
What factors are driving Meningococcal Disease Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Meningococcal Disease Vaccine market opportunities vary by end market size?
How does Meningococcal Disease Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
The global Meningococcal Disease Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Meningococcal Disease Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Meningococcal Disease Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Meningococcal Disease Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Meningococcal Disease Vaccine players cover AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi and Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
LPI (LP Information)' newest research report, the “Meningococcal Disease Vaccine Industry Forecast” looks at past sales and reviews total world Meningococcal Disease Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Meningococcal Disease Vaccine sales for 2023 through 2029. With Meningococcal Disease Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Meningococcal Disease Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Meningococcal Disease Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Disease Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Meningococcal Disease Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Disease Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Disease Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Disease Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Polysaccharide
- Conjugate
- Combination
- Infant
- Child
- Aldult
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- Johnson & Johnson
- Mylan N.V
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc
- GlaxoSmithKline plc
- Novartis AG
- Sanofi
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Baxter
- BIO-MED
- Bio-Manguinhos
- Walvax Biotechnology Co., Ltd
What is the 10-year outlook for the global Meningococcal Disease Vaccine market?
What factors are driving Meningococcal Disease Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Meningococcal Disease Vaccine market opportunities vary by end market size?
How does Meningococcal Disease Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Meningococcal Disease Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Meningococcal Disease Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Meningococcal Disease Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Meningococcal Disease Vaccine Segment by Type
2.2.1 Polysaccharide
2.2.2 Conjugate
2.2.3 Combination
2.3 Meningococcal Disease Vaccine Sales by Type
2.3.1 Global Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Meningococcal Disease Vaccine Sale Price by Type (2018-2023)
2.4 Meningococcal Disease Vaccine Segment by Application
2.4.1 Infant
2.4.2 Child
2.4.3 Aldult
2.5 Meningococcal Disease Vaccine Sales by Application
2.5.1 Global Meningococcal Disease Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Meningococcal Disease Vaccine Sale Price by Application (2018-2023)
3 GLOBAL MENINGOCOCCAL DISEASE VACCINE BY COMPANY
3.1 Global Meningococcal Disease Vaccine Breakdown Data by Company
3.1.1 Global Meningococcal Disease Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Meningococcal Disease Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Meningococcal Disease Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Meningococcal Disease Vaccine Revenue by Company (2018-2023)
3.2.2 Global Meningococcal Disease Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Meningococcal Disease Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Meningococcal Disease Vaccine Product Location Distribution
3.4.2 Players Meningococcal Disease Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Meningococcal Disease Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Meningococcal Disease Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Meningococcal Disease Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Meningococcal Disease Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Meningococcal Disease Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Meningococcal Disease Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Meningococcal Disease Vaccine Sales Growth
4.4 APAC Meningococcal Disease Vaccine Sales Growth
4.5 Europe Meningococcal Disease Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Disease Vaccine Sales Growth
5 AMERICAS
5.1 Americas Meningococcal Disease Vaccine Sales by Country
5.1.1 Americas Meningococcal Disease Vaccine Sales by Country (2018-2023)
5.1.2 Americas Meningococcal Disease Vaccine Revenue by Country (2018-2023)
5.2 Americas Meningococcal Disease Vaccine Sales by Type
5.3 Americas Meningococcal Disease Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Meningococcal Disease Vaccine Sales by Region
6.1.1 APAC Meningococcal Disease Vaccine Sales by Region (2018-2023)
6.1.2 APAC Meningococcal Disease Vaccine Revenue by Region (2018-2023)
6.2 APAC Meningococcal Disease Vaccine Sales by Type
6.3 APAC Meningococcal Disease Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Meningococcal Disease Vaccine by Country
7.1.1 Europe Meningococcal Disease Vaccine Sales by Country (2018-2023)
7.1.2 Europe Meningococcal Disease Vaccine Revenue by Country (2018-2023)
7.2 Europe Meningococcal Disease Vaccine Sales by Type
7.3 Europe Meningococcal Disease Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Meningococcal Disease Vaccine by Country
8.1.1 Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Meningococcal Disease Vaccine Sales by Type
8.3 Middle East & Africa Meningococcal Disease Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Disease Vaccine
10.4 Industry Chain Structure of Meningococcal Disease Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Meningococcal Disease Vaccine Distributors
11.3 Meningococcal Disease Vaccine Customer
12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION
12.1 Global Meningococcal Disease Vaccine Market Size Forecast by Region
12.1.1 Global Meningococcal Disease Vaccine Forecast by Region (2024-2029)
12.1.2 Global Meningococcal Disease Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Meningococcal Disease Vaccine Forecast by Type
12.7 Global Meningococcal Disease Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
13.1.3 AstraZeneca Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
13.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Mylan N.V
13.3.1 Mylan N.V Company Information
13.3.2 Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications
13.3.3 Mylan N.V Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mylan N.V Main Business Overview
13.3.5 Mylan N.V Latest Developments
13.4 Teva Pharmaceutical Industries Ltd
13.4.1 Teva Pharmaceutical Industries Ltd Company Information
13.4.2 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.4.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.5 Pfizer Inc
13.5.1 Pfizer Inc Company Information
13.5.2 Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications
13.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Pfizer Inc Main Business Overview
13.5.5 Pfizer Inc Latest Developments
13.6 GlaxoSmithKline plc
13.6.1 GlaxoSmithKline plc Company Information
13.6.2 GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications
13.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 GlaxoSmithKline plc Main Business Overview
13.6.5 GlaxoSmithKline plc Latest Developments
13.7 Novartis AG
13.7.1 Novartis AG Company Information
13.7.2 Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications
13.7.3 Novartis AG Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Novartis AG Main Business Overview
13.7.5 Novartis AG Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
13.8.3 Sanofi Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 Merck & Co., Inc.
13.9.1 Merck & Co., Inc. Company Information
13.9.2 Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
13.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Merck & Co., Inc. Main Business Overview
13.9.5 Merck & Co., Inc. Latest Developments
13.10 F. Hoffmann-La Roche Ltd
13.10.1 F. Hoffmann-La Roche Ltd Company Information
13.10.2 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.10.5 F. Hoffmann-La Roche Ltd Latest Developments
13.11 Baxter
13.11.1 Baxter Company Information
13.11.2 Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
13.11.3 Baxter Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Baxter Main Business Overview
13.11.5 Baxter Latest Developments
13.12 BIO-MED
13.12.1 BIO-MED Company Information
13.12.2 BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
13.12.3 BIO-MED Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 BIO-MED Main Business Overview
13.12.5 BIO-MED Latest Developments
13.13 Bio-Manguinhos
13.13.1 Bio-Manguinhos Company Information
13.13.2 Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications
13.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Bio-Manguinhos Main Business Overview
13.13.5 Bio-Manguinhos Latest Developments
13.14 Walvax Biotechnology Co., Ltd
13.14.1 Walvax Biotechnology Co., Ltd Company Information
13.14.2 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Walvax Biotechnology Co., Ltd Main Business Overview
13.14.5 Walvax Biotechnology Co., Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Meningococcal Disease Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Meningococcal Disease Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Meningococcal Disease Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Meningococcal Disease Vaccine Segment by Type
2.2.1 Polysaccharide
2.2.2 Conjugate
2.2.3 Combination
2.3 Meningococcal Disease Vaccine Sales by Type
2.3.1 Global Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Meningococcal Disease Vaccine Sale Price by Type (2018-2023)
2.4 Meningococcal Disease Vaccine Segment by Application
2.4.1 Infant
2.4.2 Child
2.4.3 Aldult
2.5 Meningococcal Disease Vaccine Sales by Application
2.5.1 Global Meningococcal Disease Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Meningococcal Disease Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Meningococcal Disease Vaccine Sale Price by Application (2018-2023)
3 GLOBAL MENINGOCOCCAL DISEASE VACCINE BY COMPANY
3.1 Global Meningococcal Disease Vaccine Breakdown Data by Company
3.1.1 Global Meningococcal Disease Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Meningococcal Disease Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Meningococcal Disease Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Meningococcal Disease Vaccine Revenue by Company (2018-2023)
3.2.2 Global Meningococcal Disease Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Meningococcal Disease Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Meningococcal Disease Vaccine Product Location Distribution
3.4.2 Players Meningococcal Disease Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Meningococcal Disease Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Meningococcal Disease Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Meningococcal Disease Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Meningococcal Disease Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Meningococcal Disease Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Meningococcal Disease Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Meningococcal Disease Vaccine Sales Growth
4.4 APAC Meningococcal Disease Vaccine Sales Growth
4.5 Europe Meningococcal Disease Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Disease Vaccine Sales Growth
5 AMERICAS
5.1 Americas Meningococcal Disease Vaccine Sales by Country
5.1.1 Americas Meningococcal Disease Vaccine Sales by Country (2018-2023)
5.1.2 Americas Meningococcal Disease Vaccine Revenue by Country (2018-2023)
5.2 Americas Meningococcal Disease Vaccine Sales by Type
5.3 Americas Meningococcal Disease Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Meningococcal Disease Vaccine Sales by Region
6.1.1 APAC Meningococcal Disease Vaccine Sales by Region (2018-2023)
6.1.2 APAC Meningococcal Disease Vaccine Revenue by Region (2018-2023)
6.2 APAC Meningococcal Disease Vaccine Sales by Type
6.3 APAC Meningococcal Disease Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Meningococcal Disease Vaccine by Country
7.1.1 Europe Meningococcal Disease Vaccine Sales by Country (2018-2023)
7.1.2 Europe Meningococcal Disease Vaccine Revenue by Country (2018-2023)
7.2 Europe Meningococcal Disease Vaccine Sales by Type
7.3 Europe Meningococcal Disease Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Meningococcal Disease Vaccine by Country
8.1.1 Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Meningococcal Disease Vaccine Sales by Type
8.3 Middle East & Africa Meningococcal Disease Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Disease Vaccine
10.4 Industry Chain Structure of Meningococcal Disease Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Meningococcal Disease Vaccine Distributors
11.3 Meningococcal Disease Vaccine Customer
12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL DISEASE VACCINE BY GEOGRAPHIC REGION
12.1 Global Meningococcal Disease Vaccine Market Size Forecast by Region
12.1.1 Global Meningococcal Disease Vaccine Forecast by Region (2024-2029)
12.1.2 Global Meningococcal Disease Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Meningococcal Disease Vaccine Forecast by Type
12.7 Global Meningococcal Disease Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
13.1.3 AstraZeneca Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
13.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Mylan N.V
13.3.1 Mylan N.V Company Information
13.3.2 Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications
13.3.3 Mylan N.V Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mylan N.V Main Business Overview
13.3.5 Mylan N.V Latest Developments
13.4 Teva Pharmaceutical Industries Ltd
13.4.1 Teva Pharmaceutical Industries Ltd Company Information
13.4.2 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.4.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.5 Pfizer Inc
13.5.1 Pfizer Inc Company Information
13.5.2 Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications
13.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Pfizer Inc Main Business Overview
13.5.5 Pfizer Inc Latest Developments
13.6 GlaxoSmithKline plc
13.6.1 GlaxoSmithKline plc Company Information
13.6.2 GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications
13.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 GlaxoSmithKline plc Main Business Overview
13.6.5 GlaxoSmithKline plc Latest Developments
13.7 Novartis AG
13.7.1 Novartis AG Company Information
13.7.2 Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications
13.7.3 Novartis AG Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Novartis AG Main Business Overview
13.7.5 Novartis AG Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
13.8.3 Sanofi Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 Merck & Co., Inc.
13.9.1 Merck & Co., Inc. Company Information
13.9.2 Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
13.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Merck & Co., Inc. Main Business Overview
13.9.5 Merck & Co., Inc. Latest Developments
13.10 F. Hoffmann-La Roche Ltd
13.10.1 F. Hoffmann-La Roche Ltd Company Information
13.10.2 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.10.5 F. Hoffmann-La Roche Ltd Latest Developments
13.11 Baxter
13.11.1 Baxter Company Information
13.11.2 Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
13.11.3 Baxter Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Baxter Main Business Overview
13.11.5 Baxter Latest Developments
13.12 BIO-MED
13.12.1 BIO-MED Company Information
13.12.2 BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
13.12.3 BIO-MED Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 BIO-MED Main Business Overview
13.12.5 BIO-MED Latest Developments
13.13 Bio-Manguinhos
13.13.1 Bio-Manguinhos Company Information
13.13.2 Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications
13.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Bio-Manguinhos Main Business Overview
13.13.5 Bio-Manguinhos Latest Developments
13.14 Walvax Biotechnology Co., Ltd
13.14.1 Walvax Biotechnology Co., Ltd Company Information
13.14.2 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
13.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Walvax Biotechnology Co., Ltd Main Business Overview
13.14.5 Walvax Biotechnology Co., Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Meningococcal Disease Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Meningococcal Disease Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Polysaccharide
Table 4. Major Players of Conjugate
Table 5. Major Players of Combination
Table 6. Global Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 7. Global Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Table 8. Global Meningococcal Disease Vaccine Revenue by Type (2018-2023) & ($ million)
Table 9. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2018-2023)
Table 10. Global Meningococcal Disease Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 12. Global Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Table 13. Global Meningococcal Disease Vaccine Revenue by Application (2018-2023)
Table 14. Global Meningococcal Disease Vaccine Revenue Market Share by Application (2018-2023)
Table 15. Global Meningococcal Disease Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Meningococcal Disease Vaccine Sales by Company (2018-2023) & (K Units)
Table 17. Global Meningococcal Disease Vaccine Sales Market Share by Company (2018-2023)
Table 18. Global Meningococcal Disease Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Meningococcal Disease Vaccine Revenue Market Share by Company (2018-2023)
Table 20. Global Meningococcal Disease Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution and Sales Area
Table 22. Players Meningococcal Disease Vaccine Products Offered
Table 23. Meningococcal Disease Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Meningococcal Disease Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Meningococcal Disease Vaccine Sales Market Share Geographic Region (2018-2023)
Table 28. Global Meningococcal Disease Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Meningococcal Disease Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Meningococcal Disease Vaccine Sales Market Share by Country/Region (2018-2023)
Table 32. Global Meningococcal Disease Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Meningococcal Disease Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)
Table 35. Americas Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)
Table 36. Americas Meningococcal Disease Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)
Table 38. Americas Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 39. Americas Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 40. APAC Meningococcal Disease Vaccine Sales by Region (2018-2023) & (K Units)
Table 41. APAC Meningococcal Disease Vaccine Sales Market Share by Region (2018-2023)
Table 42. APAC Meningococcal Disease Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Meningococcal Disease Vaccine Revenue Market Share by Region (2018-2023)
Table 44. APAC Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 45. APAC Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 46. Europe Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)
Table 47. Europe Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)
Table 48. Europe Meningococcal Disease Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)
Table 50. Europe Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 51. Europe Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Meningococcal Disease Vaccine
Table 59. Key Market Challenges & Risks of Meningococcal Disease Vaccine
Table 60. Key Industry Trends of Meningococcal Disease Vaccine
Table 61. Meningococcal Disease Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Meningococcal Disease Vaccine Distributors List
Table 64. Meningococcal Disease Vaccine Customer List
Table 65. Global Meningococcal Disease Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Meningococcal Disease Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Meningococcal Disease Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Meningococcal Disease Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Meningococcal Disease Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Meningococcal Disease Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Meningococcal Disease Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Meningococcal Disease Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. AstraZeneca Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 81. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. AstraZeneca Main Business
Table 83. AstraZeneca Latest Developments
Table 84. Johnson & Johnson Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 86. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Johnson & Johnson Main Business
Table 88. Johnson & Johnson Latest Developments
Table 89. Mylan N.V Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 91. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Mylan N.V Main Business
Table 93. Mylan N.V Latest Developments
Table 94. Teva Pharmaceutical Industries Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 96. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Teva Pharmaceutical Industries Ltd Main Business
Table 98. Teva Pharmaceutical Industries Ltd Latest Developments
Table 99. Pfizer Inc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 101. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Pfizer Inc Main Business
Table 103. Pfizer Inc Latest Developments
Table 104. GlaxoSmithKline plc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 106. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. GlaxoSmithKline plc Main Business
Table 108. GlaxoSmithKline plc Latest Developments
Table 109. Novartis AG Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 111. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Novartis AG Main Business
Table 113. Novartis AG Latest Developments
Table 114. Sanofi Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 116. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Sanofi Main Business
Table 118. Sanofi Latest Developments
Table 119. Merck & Co., Inc. Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 121. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Merck & Co., Inc. Main Business
Table 123. Merck & Co., Inc. Latest Developments
Table 124. F. Hoffmann-La Roche Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 126. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. F. Hoffmann-La Roche Ltd Main Business
Table 128. F. Hoffmann-La Roche Ltd Latest Developments
Table 129. Baxter Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 131. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Baxter Main Business
Table 133. Baxter Latest Developments
Table 134. BIO-MED Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 136. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. BIO-MED Main Business
Table 138. BIO-MED Latest Developments
Table 139. Bio-Manguinhos Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 141. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Bio-Manguinhos Main Business
Table 143. Bio-Manguinhos Latest Developments
Table 144. Walvax Biotechnology Co., Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 146. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Walvax Biotechnology Co., Ltd Main Business
Table 148. Walvax Biotechnology Co., Ltd Latest Developments
Table 1. Meningococcal Disease Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Meningococcal Disease Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Polysaccharide
Table 4. Major Players of Conjugate
Table 5. Major Players of Combination
Table 6. Global Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 7. Global Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Table 8. Global Meningococcal Disease Vaccine Revenue by Type (2018-2023) & ($ million)
Table 9. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2018-2023)
Table 10. Global Meningococcal Disease Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 12. Global Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Table 13. Global Meningococcal Disease Vaccine Revenue by Application (2018-2023)
Table 14. Global Meningococcal Disease Vaccine Revenue Market Share by Application (2018-2023)
Table 15. Global Meningococcal Disease Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Meningococcal Disease Vaccine Sales by Company (2018-2023) & (K Units)
Table 17. Global Meningococcal Disease Vaccine Sales Market Share by Company (2018-2023)
Table 18. Global Meningococcal Disease Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Meningococcal Disease Vaccine Revenue Market Share by Company (2018-2023)
Table 20. Global Meningococcal Disease Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Meningococcal Disease Vaccine Producing Area Distribution and Sales Area
Table 22. Players Meningococcal Disease Vaccine Products Offered
Table 23. Meningococcal Disease Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Meningococcal Disease Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Meningococcal Disease Vaccine Sales Market Share Geographic Region (2018-2023)
Table 28. Global Meningococcal Disease Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Meningococcal Disease Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Meningococcal Disease Vaccine Sales Market Share by Country/Region (2018-2023)
Table 32. Global Meningococcal Disease Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Meningococcal Disease Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)
Table 35. Americas Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)
Table 36. Americas Meningococcal Disease Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)
Table 38. Americas Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 39. Americas Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 40. APAC Meningococcal Disease Vaccine Sales by Region (2018-2023) & (K Units)
Table 41. APAC Meningococcal Disease Vaccine Sales Market Share by Region (2018-2023)
Table 42. APAC Meningococcal Disease Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Meningococcal Disease Vaccine Revenue Market Share by Region (2018-2023)
Table 44. APAC Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 45. APAC Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 46. Europe Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)
Table 47. Europe Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)
Table 48. Europe Meningococcal Disease Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)
Table 50. Europe Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 51. Europe Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Meningococcal Disease Vaccine Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Meningococcal Disease Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Meningococcal Disease Vaccine Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Meningococcal Disease Vaccine Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Meningococcal Disease Vaccine
Table 59. Key Market Challenges & Risks of Meningococcal Disease Vaccine
Table 60. Key Industry Trends of Meningococcal Disease Vaccine
Table 61. Meningococcal Disease Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Meningococcal Disease Vaccine Distributors List
Table 64. Meningococcal Disease Vaccine Customer List
Table 65. Global Meningococcal Disease Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Meningococcal Disease Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Meningococcal Disease Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Meningococcal Disease Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Meningococcal Disease Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Meningococcal Disease Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Meningococcal Disease Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Meningococcal Disease Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Meningococcal Disease Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Meningococcal Disease Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. AstraZeneca Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. AstraZeneca Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 81. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. AstraZeneca Main Business
Table 83. AstraZeneca Latest Developments
Table 84. Johnson & Johnson Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Johnson & Johnson Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 86. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Johnson & Johnson Main Business
Table 88. Johnson & Johnson Latest Developments
Table 89. Mylan N.V Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Mylan N.V Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 91. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Mylan N.V Main Business
Table 93. Mylan N.V Latest Developments
Table 94. Teva Pharmaceutical Industries Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 96. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Teva Pharmaceutical Industries Ltd Main Business
Table 98. Teva Pharmaceutical Industries Ltd Latest Developments
Table 99. Pfizer Inc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Pfizer Inc Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 101. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Pfizer Inc Main Business
Table 103. Pfizer Inc Latest Developments
Table 104. GlaxoSmithKline plc Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. GlaxoSmithKline plc Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 106. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. GlaxoSmithKline plc Main Business
Table 108. GlaxoSmithKline plc Latest Developments
Table 109. Novartis AG Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Novartis AG Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 111. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Novartis AG Main Business
Table 113. Novartis AG Latest Developments
Table 114. Sanofi Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Sanofi Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 116. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Sanofi Main Business
Table 118. Sanofi Latest Developments
Table 119. Merck & Co., Inc. Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Merck & Co., Inc. Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 121. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Merck & Co., Inc. Main Business
Table 123. Merck & Co., Inc. Latest Developments
Table 124. F. Hoffmann-La Roche Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 126. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. F. Hoffmann-La Roche Ltd Main Business
Table 128. F. Hoffmann-La Roche Ltd Latest Developments
Table 129. Baxter Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Baxter Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 131. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Baxter Main Business
Table 133. Baxter Latest Developments
Table 134. BIO-MED Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. BIO-MED Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 136. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. BIO-MED Main Business
Table 138. BIO-MED Latest Developments
Table 139. Bio-Manguinhos Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Bio-Manguinhos Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 141. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Bio-Manguinhos Main Business
Table 143. Bio-Manguinhos Latest Developments
Table 144. Walvax Biotechnology Co., Ltd Basic Information, Meningococcal Disease Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product Portfolios and Specifications
Table 146. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Walvax Biotechnology Co., Ltd Main Business
Table 148. Walvax Biotechnology Co., Ltd Latest Developments
LIST OF FIGURES
Figure 1. Picture of Meningococcal Disease Vaccine
Figure 2. Meningococcal Disease Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Disease Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Meningococcal Disease Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Meningococcal Disease Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Polysaccharide
Figure 10. Product Picture of Conjugate
Figure 11. Product Picture of Combination
Figure 12. Global Meningococcal Disease Vaccine Sales Market Share by Type in 2022
Figure 13. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2018-2023)
Figure 14. Meningococcal Disease Vaccine Consumed in Infant
Figure 15. Global Meningococcal Disease Vaccine Market: Infant (2018-2023) & (K Units)
Figure 16. Meningococcal Disease Vaccine Consumed in Child
Figure 17. Global Meningococcal Disease Vaccine Market: Child (2018-2023) & (K Units)
Figure 18. Meningococcal Disease Vaccine Consumed in Aldult
Figure 19. Global Meningococcal Disease Vaccine Market: Aldult (2018-2023) & (K Units)
Figure 20. Global Meningococcal Disease Vaccine Sales Market Share by Application (2022)
Figure 21. Global Meningococcal Disease Vaccine Revenue Market Share by Application in 2022
Figure 22. Meningococcal Disease Vaccine Sales Market by Company in 2022 (K Units)
Figure 23. Global Meningococcal Disease Vaccine Sales Market Share by Company in 2022
Figure 24. Meningococcal Disease Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Meningococcal Disease Vaccine Revenue Market Share by Company in 2022
Figure 26. Global Meningococcal Disease Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Meningococcal Disease Vaccine Sales 2018-2023 (K Units)
Figure 29. Americas Meningococcal Disease Vaccine Revenue 2018-2023 ($ Millions)
Figure 30. APAC Meningococcal Disease Vaccine Sales 2018-2023 (K Units)
Figure 31. APAC Meningococcal Disease Vaccine Revenue 2018-2023 ($ Millions)
Figure 32. Europe Meningococcal Disease Vaccine Sales 2018-2023 (K Units)
Figure 33. Europe Meningococcal Disease Vaccine Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Meningococcal Disease Vaccine Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Meningococcal Disease Vaccine Revenue 2018-2023 ($ Millions)
Figure 36. Americas Meningococcal Disease Vaccine Sales Market Share by Country in 2022
Figure 37. Americas Meningococcal Disease Vaccine Revenue Market Share by Country in 2022
Figure 38. Americas Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Figure 39. Americas Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Figure 40. United States Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Meningococcal Disease Vaccine Sales Market Share by Region in 2022
Figure 45. APAC Meningococcal Disease Vaccine Revenue Market Share by Regions in 2022
Figure 46. APAC Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Figure 47. APAC Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Figure 48. China Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Meningococcal Disease Vaccine Sales Market Share by Country in 2022
Figure 56. Europe Meningococcal Disease Vaccine Revenue Market Share by Country in 2022
Figure 57. Europe Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Figure 58. Europe Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Figure 59. Germany Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Figure 68. Egypt Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine in 2022
Figure 74. Manufacturing Process Analysis of Meningococcal Disease Vaccine
Figure 75. Industry Chain Structure of Meningococcal Disease Vaccine
Figure 76. Channels of Distribution
Figure 77. Global Meningococcal Disease Vaccine Sales Market Forecast by Region (2024-2029)
Figure 78. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Meningococcal Disease Vaccine
Figure 2. Meningococcal Disease Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Disease Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Meningococcal Disease Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Meningococcal Disease Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Polysaccharide
Figure 10. Product Picture of Conjugate
Figure 11. Product Picture of Combination
Figure 12. Global Meningococcal Disease Vaccine Sales Market Share by Type in 2022
Figure 13. Global Meningococcal Disease Vaccine Revenue Market Share by Type (2018-2023)
Figure 14. Meningococcal Disease Vaccine Consumed in Infant
Figure 15. Global Meningococcal Disease Vaccine Market: Infant (2018-2023) & (K Units)
Figure 16. Meningococcal Disease Vaccine Consumed in Child
Figure 17. Global Meningococcal Disease Vaccine Market: Child (2018-2023) & (K Units)
Figure 18. Meningococcal Disease Vaccine Consumed in Aldult
Figure 19. Global Meningococcal Disease Vaccine Market: Aldult (2018-2023) & (K Units)
Figure 20. Global Meningococcal Disease Vaccine Sales Market Share by Application (2022)
Figure 21. Global Meningococcal Disease Vaccine Revenue Market Share by Application in 2022
Figure 22. Meningococcal Disease Vaccine Sales Market by Company in 2022 (K Units)
Figure 23. Global Meningococcal Disease Vaccine Sales Market Share by Company in 2022
Figure 24. Meningococcal Disease Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Meningococcal Disease Vaccine Revenue Market Share by Company in 2022
Figure 26. Global Meningococcal Disease Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Meningococcal Disease Vaccine Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Meningococcal Disease Vaccine Sales 2018-2023 (K Units)
Figure 29. Americas Meningococcal Disease Vaccine Revenue 2018-2023 ($ Millions)
Figure 30. APAC Meningococcal Disease Vaccine Sales 2018-2023 (K Units)
Figure 31. APAC Meningococcal Disease Vaccine Revenue 2018-2023 ($ Millions)
Figure 32. Europe Meningococcal Disease Vaccine Sales 2018-2023 (K Units)
Figure 33. Europe Meningococcal Disease Vaccine Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Meningococcal Disease Vaccine Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Meningococcal Disease Vaccine Revenue 2018-2023 ($ Millions)
Figure 36. Americas Meningococcal Disease Vaccine Sales Market Share by Country in 2022
Figure 37. Americas Meningococcal Disease Vaccine Revenue Market Share by Country in 2022
Figure 38. Americas Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Figure 39. Americas Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Figure 40. United States Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Meningococcal Disease Vaccine Sales Market Share by Region in 2022
Figure 45. APAC Meningococcal Disease Vaccine Revenue Market Share by Regions in 2022
Figure 46. APAC Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Figure 47. APAC Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Figure 48. China Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Meningococcal Disease Vaccine Sales Market Share by Country in 2022
Figure 56. Europe Meningococcal Disease Vaccine Revenue Market Share by Country in 2022
Figure 57. Europe Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Figure 58. Europe Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Figure 59. Germany Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Meningococcal Disease Vaccine Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Meningococcal Disease Vaccine Sales Market Share by Application (2018-2023)
Figure 68. Egypt Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Meningococcal Disease Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine in 2022
Figure 74. Manufacturing Process Analysis of Meningococcal Disease Vaccine
Figure 75. Industry Chain Structure of Meningococcal Disease Vaccine
Figure 76. Channels of Distribution
Figure 77. Global Meningococcal Disease Vaccine Sales Market Forecast by Region (2024-2029)
Figure 78. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Meningococcal Disease Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Meningococcal Disease Vaccine Revenue Market Share Forecast by Application (2024-2029)
